Clinical Study of Bufei Huoxue Decoction in Promoting Rapid Postoperative Recovery of Patients with Non-Small Cell Lung Cancer

OBJECTIVE To observe the effect of Bufei Huoxue Decoction on promoting the rapid postoperative recovery of non-small cell lung cancer (NSCLC) patients with deficiency of lung and spleen along with phlegm and blood-stasis. METHODS 107 patients with lung and spleen deficiency along with phlegm and blood stasis type non-small cell lung cancer were randomly divided into the treatment group and the control group， and both were given surgery therapy. The treatment group has been given Bufei Huoxue Decoction， one dose a day， 1 day before surgery and 5 days after surgery. After 5 days' treatment， the clinical efficacy， traditional Chinese medicine (TCM) syndrome scores， postoperative inflammation indicators， conditions of complications and rehabilitation were compared between the two groups. RESULTS The scores of TCM syndromes in the two groups were significantly improved after surgery (P<0.05，P<0.01) and the treatment group was better (P<0.05). The total clinical effective rate of the treatment group was higher than that of the control group (P<0.05). C-reactive protein (CRP)， interleukin-6 (IL-6)， and tumor necrosis factor-α (TNF-α) in the treatment group were lower than those in the control group on the 3rd and 5th day after surgery (P<0.05). Postoperative thoracic drainage， postoperative bedtime and hospital days in the treatment group were less than those in the control group (P<0.05). The partial arterial oxygen pressure (PaO₂) on the 5th day after surgery in the treatment group was higher than that of the control group (P<0.05). CONCLUSION Bufei Huoxue Decoction can reduce the postoperative inflammatory response of patients with non-small cell lung cancer and promote rapid recovery， in line with the concept of accelerated rehabilitation surgery and is worthy of further promotion and application.